BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BMEYE Launches a Noninvasive, Breakthrough Parameter for Delivery of Oxygen (DO2I) and new Fluid Management Parameters at the European Society of Anesthesia Congress


6/14/2011 9:03:23 AM

AMSTERDAM, June 14, 2011 /PRNewswire/ --


BMEYE B.V., the inventor of noninvasive, beat-to-beat cardiac output and blood pressure monitoring, announces the launch of DO2I - the delivery of oxygen to the tissues. DO2I is the multiple of cardiac output, oxygen saturation and hemoglobin and is a critical parameter for clinicians. This new parameter is made available noninvasively for the first time by the combination of two innovative technologies: the BMEYE Nexfin CO-TREK for noninvasive and continuous cardiac output monitoring and the Masimo Rainbow SET for noninvasive and continuous hemoglobin and oxygen saturation monitoring. In addition BMEYE launched two new parameters, Pulse Pressure Variation (PPV) and Stroke Volume Variation (SVV), which are essential for monitoring of the fluid responsiveness status of the patient. All variables provided are real-time, beat-to-beat measurements of hemodynamic parameters, which enable clinicians to detect impending hemodynamic crisis and optimize treatment before tissue hypoxia and organ injury ensues in peri-operative period and in critical care.

Hemodynamic monitoring has traditionally relied upon invasive, costly, intermittent, or unreliable methods to assist clinicians in maintaining adequate oxygen delivery, tissue perfusion and to prevent hypoxia and its irreversible damage. However, the ccNexfin with Masimo Rainbow SET offers a totally noninvasive method of providing some of the most advanced cardiovascular and hemodynamic monitoring capabilities available today. It utilizes a BMEYE finger cuff to capture and continuously measure beat-to-beat blood pressure, mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), dynamic fluid responsiveness parameters (PPV, SVV), index of contractility (dP/dt) and a Masimo finger sensor to noninvasively and continuously measure hemoglobin (SpHb®), oxygen saturation (SpO2), and perfusion index (PI). The combined technologies provide the unique parameter oxygen delivery (DO2I).

These integrated functional hemodynamic monitoring data allow clinicians to predict and proactively address the early signs of hemodynamic instability during the peri-operative period and in critical situations.

"With the integration of PPV and SVV we further strengthen our ccNexfin product offering, with the addition of DO2I we take hemodynamic monitoring to the next level" stated Rob de Ree, CEO of BMEYE. "We are proud to be the first company to provide this parameter to the clinic and combined with the available parameters in the ccNexfin to have the potential to provide earlier diagnosis and early goal-directed therapies in anesthesia and emergency care to improve patient care while reducing costs."

Prof. Azriel Perel from the Tel Aviv University stated: "For me personally it is a dream come true. For the first time we have a totally noninvasive advanced hemodynamic monitor which can provide us with continuous DO2I within minutes without the complications that are associated with traditional invasive techniques. This is a great step forward in the management of patients in the operating room and the intensive care unit. I believe that by making s DO2I and fluid responsiveness parameters available noninvasively, in addition to cardiac output and blood pressure the ccNexfin has the potential to change medical practice in the peri-operative setting."

About BMEYE


BMEYE, a Dutch company based in Amsterdam, The Netherlands, develops innovative medical devices with broad application in clinical settings that require cardiovascular monitoring. Specifically, BMEYE produces patient monitors that noninvasively measure continuous blood pressure and cardiac output. BMEYE's mission: BMEYE is the premier provider and will set the standard of noninvasive, beat-to-beat, user-friendly cardiovascular monitoring systems, to improve patient care and reduce healthcare costs.




Read at BioSpace.com

BMEYE
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES